Ozempic and Wegovy officially moved off FDA’s drug shortage list
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list nearly four months after the agency found the drugs to be available.
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.
FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk announced.On Feb. 21, the FDA updated its drug shortage list and listed the shortage of all doses of injectable semaglutide (Ozempic/Wegovy) as being resolved.
Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Ozempic, Wegovy Shortage Is Officially Over
The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current and projected U.S. demand. The injectable formulation of the GLP-1 receptor agonist has been in shortage since August 2022 due to increased demand.
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Fierce Healthcare2h
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
FiercePharma8h
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Medpage Today on MSN1d
Semaglutide Tied to Small Risk of Potentially Blinding Eye Condition
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
Money Morning2h
Ozempic Maker Is Ready to Fight Back Against Hims & Hers
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Semaglutide Side Effects: Is It Safe? What You Need To Know
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
ABC News on MSN9d
Weight loss drug semaglutide may reduce alcohol cravings, heavy drinking and smoking, new study finds
Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...
Rolling Out3h
How this diabetes drug is transforming heart health
Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.
Why Hims & Hers Health Stock Is Plummeting Today
Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...